Tango Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview

Tango Therapeutics

02/08/2024 17:30

* Tango Therapeutics Inc  TNGX.OQ   TNGX.O  is expected
to show a
fall in quarterly revenue when it reports  results on August 5
(estimated) for the period ending June 30 2024
    * The Boston Massachusetts-based  company is expected to
report a
49.2% decrease in revenue to $7.423 million from $14.6 million a
year ago, according to the mean estimate from 10 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Tango Therapeutics Inc
is for
a loss of 34 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Tango
Therapeutics Inc is $15.00​, above​ its last closing price
of $9.45. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.31       -0.31      -0.35     Missed  -11.9
 Dec. 31 2024  -0.30       -0.28      -0.32     Missed  -15.2
 Sep. 30 2023  -0.34       -0.34      -0.23     Beat    33.3​
 Jun. 30 2023  -0.31       -0.34      -0.23     Beat    31.5
 ​​Mar.        -0.35       -0.35      -0.32     Beat    8.9
 31 2023                                                
 Dec. 31 2022              -0.35      -0.33     Beat    7​
 Sep. 30 2022  -0.32       -0.32      -0.33     Missed  -2.1
 Jun. 30 2022  -0.32       -0.32      -0.28     Beat    13.6
 This summary was machine generated August 2 at 16:30 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)